Maxacalcitol therapy decreases circulating osteoprotegerin levels in dialysis patients with secondary hyperparathyroidism

Clinical Nephrology

Volumn 64, Issue 1, 2005, Pages 64-68

  Kazama, J J ^a   Omori, K ^a   Takahashi, N ^a   Ito, Y ^a   Maruyama, H ^a   Narita, I ^a   Gejyo, F ^a   Iwasaki, Y ^b   Fukagawa, M ^c  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b OITA UNIVERSITY OF NURSING AND HEALTH SCIENCES   (Japan)

^c KOBE UNIVERSITY HOSPITAL   (Japan)

Author keywords

Maxacalcitol therapy; Osteoprotegerin; PTH vitamin D

Indexed keywords

22 OXACALCITRIOL; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM ION; OSTEOCALCIN; OSTEOPROTEGERIN; PARATHYROID HORMONE; VITAMIN D;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC GLOMERULONEPHRITIS; CLINICAL ARTICLE; DIABETIC NEPHROPATHY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; IN VITRO STUDY; KIDNEY POLYCYSTIC DISEASE; LONG TERM CARE; MALE; NEPHROSCLEROSIS; PARATHYROID HORMONE BLOOD LEVEL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SECONDARY HYPERPARATHYROIDISM;

EID: 22144473687     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp64064     Document Type: Article

References (21)

1. Coen G, Ballanti P, Balducci A, Calabria S, Fischer MS, Jankovic L, Manni M, Morosetti M, Moscaritolo E, Sardella D, Bonucci E 2002 Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant 17: 233-238
2. Gori F, Hofbauer LC, Dunstan CR, Spelsberg TC, Khosla S, Riggs BL 2000 The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology 141: 4768-4776
3. Haas M, Leko-Mohr Z, Roschger P, Kletzmayr J, Schwarz C, Domenig C, Zsontsich T, Klaushofer K, Delling G, Oberbauer R 2002 Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. Am J Kidney Dis 39: 580-586
4. Hofbauer LC, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S 1998 Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun 250: 776-781
5. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL 2000 The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15: 2-12
6. Kazama JJ, Maruyama H, Gejyo F 2001 Osteoclastogenesis and osteoclast activation in dialysis-related amyloid osteopathy. Am J Kidney Dis 38 (4 Suppl 1): S175-177
7. Kazama JJ, Shigematsu T, Tsuda E, Yano K, Miura M, Kawaguchi Y, Gejyo F, Kurokawa K, Fukagawa M 2002a Increased circulating levels of osteoclastogenesis inhibitory factor/osteoprotegerin in patients with chronic renal failure: possible roles in skeletal resistance to PTH in uremia. Am J Kidney Dis 39: 525-532
8. Kazama JJ, Kato H, Sato T, Shigematsu T, Fukagawa M, Iwasaki Y, Gejyo F 2002b Circulating osteoprotegerin is not removed through haemodialysis membrane. Nephrol Dial Transplant 17: 1860-1861
9. Kazama JJ 2004 Osteoprotegerin and bone mineral metabolism in renal failure. Curr Opin Nephrol Hypertens 13: 411-415
10. Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles PR, Chandrasekhar S, Martin TJ, Onyia JE 2001 Catabolic effects of continuous human PTH(1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 142: 4047-4054
11. Monier-Faugère MC, Geng Z, Friedler RM, Qi Q, Kubodera N, Slatopolsky E, Malluche HH 1999 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure. Kidney Int 55: 821-832
12. Nakamura H, Tsuji T, Hirata A, Yamamoto T 2002 Localization of osteoprotegerin (OPG) on bone surfaces and cement lines in rat tibia. J Histochem Cytochem 50: 945-953
13. Nishii Y, Okano T 2001 History of the development of new vitamin D analogs: studies on 22-oxacalcitriol (OCT) and 2beta-(3-hydroxypropoxy)calcitriol (ED-71). Steroids 66: 137-146
14. Nitta K, Akiba T, Uchida K, Kawashima A, Yumura W, Kabaya T, Nihei H 2003 The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis 42: 303-309
15. Onyia JE, Miles RR, Yang X, Halladay DL, Hale J, Glasebrook A, McClure D, Seno G, Churgay L, Chandrasekhar S, Martin TJ 2000 In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. J Bone Miner Res 15: 863-871
16. Sasaki N, Kusano E, Ando Y, Yano K, Tsuda E, Asano Y 2001 Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. Nephrol Dial Transplant 16: 479-482
17. Sasaki N, Kusano E, Ando Y, Nemoto J, Iimura O, Ito C, Takeda S, Yano K, Tsuda E, Asano Y 2002 Changes in osteoprotegerin and markers of bone metabolism during glucocorticoid treatment in patients with chronic glomerulonephritis. Bone 30: 853-888
18. Seidel C, Hjertner O, Abildgaard N, Heickendorff L, Hjorth M, Westin J, Nielsen JL, Hjorth-Hansen H, Waage A, Sundan A, Borset M, Nordic Myeloma Study Group 2001 Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 98: 2269-2271
19. Tsukamoto Y, Hanaoka M, Matsuo T, Saruta T, Nomura M, Takahashi Y 2000 Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism. Am J Kidney Dis 35: 458-464
20. Udagawa N, Takahashi N, Yasuda H, Mizuno A, Itoh K, Ueno Y, Shinki T, Gillespie MT, Martin TJ, Higashio K, Suda T 2000 Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 141: 3478-3484
21. Ziolkowska M, Kurowska M, Radzikowska A, Luszczykiewicz G, Wiland P, Dziewczopolski W, Filipowicz-Sosnowska A, Pazdur J, Szechinski J, Kowalczewski J, Rell-Bakalarska M, Maslinski W 2002 High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum 46: 1744-1753